Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer

Arrigo F G Cicero, Olta Allkanjari, Gian Maria Busetto, Tommaso Cai, Gaetano Larganà, Vittorio Magri, Gianpaolo Perletti, Francesco Saverio Robustelli Della Cuna, Giorgio Ivan Russo, Kostantinos Stamatiou, Alberto Trinchieri, Annabella Vitalone. Arch Ital Urol Androl. 2019 Oct 2;91(3).

ReviewHumans

Design

Review

Subjects

Not stated in the abstract

Dose used in the study

Not stated in the abstract

Duration

Not stated in the abstract

What was measured

What nutraceuticals, including palmitoylethanolamide, might offer for benign prostatic hyperplasia, prostatitis, chronic pelvic pain syndrome and prostate cancer

What the authors reported

The review covers Serenoa repens, Pygeum, Urtica, lycopene, selenium, pollen extract, beta-sitosterol and polyphenols. It describes palmitoylethanolamide in one sentence as an endogenous fatty acid amide with anti-inflammatory and neuroprotective effects that the authors say can have a role in chronic pelvic pain syndrome and chronic urological pain. No PEA trial data are given.

Limits of this study

A narrative review; palmitoylethanolamide is a minor mention with no data cited in the abstract. Funding and conflicts not stated in the abstract.

Source

PubMed 31577095 · doi:10.4081/aiua.2019.3.139

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.